The FDA’s recently released naming guidance has several key additions and changes you must understand when developing names. Failure to follow the guidelines could create confusion and lead to medication errors.
No one test or standard is adequate to determine whether a proposed name might contribute to medication errors. The FDA advocates the use of a combination of different, complementary tests to identify and remedy potential sound-alike and look-alike confusion with existing drug names.
Fortunately, our speaker is an international leader in preventing medication errors due to brand name confusion. The webinar will explain the FDA’s current thinking on best practices for developing and selecting proposed proprietary names.
Key Webinar Takeaways:
How the prescreening process relates to attributes that may contribute to medication errors in naming drugs
Suggested methods of evaluating the risk of medication errors related to naming
The FDA process for notifying applicants that have similar names in the FDA queue
The phonetic and orthographic computer analysis (POCA) criteria and its use in evaluating name similarity.